Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

R547

R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively[1][2][3][4][5].

Product Specifications

CAS Number

[741713-40-6]

UNSPSC

12352005

Hazard Statement

H301, H311, H331

Target

Apoptosis; CDK; GSK-3

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/R547.html

Purity

99.57

Solubility

10 mM in DMSO

Smiles

O=S(N1CCC(NC2=NC(N)=C(C(C3=C(C(F)=CC=C3OC)F)=O)C=N2)CC1)(C)=O

Molecular Formula

C18H21F2N5O4S

Molecular Weight

441.45

Precautions

H301, H311, H331

References & Citations

[1]Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer P, Yin X, Smith MA, Higgins BX, Chen Y, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N.Discovery of [4-Amino-2- (1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl] (2,3-difluoro-6- methoxyphenyl) methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.J Med Chem. 2006 Nov 2;49 (22) :6549-60.|[2]Bayés M, Rabasseda X, Prous JR.Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jul-Aug;29 (6) :427-37.|[3]Martin F, Thomson TM, Sewer A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, Peitsch MC.Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks.BMC Syst Biol. 2012 May 31;6:54.|[4]DePinto, Wanda et al In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials Molecular Cancer Therapeutics (2006), 5 (11), 2644-2658|[5]Jones, Clifford D.; Andrews, David M. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors Bioorganic & Medicinal Chemistry Letters (2008), 18 (24), 6486-6489

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Phase 1

Isoform

CDK1; CDK2; CDK3; CDK4; CDK5; CDK6; CDK7; GSK-3α; GSK-3β

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Lentiviral human AGBL3 shRNA (UAS) - Lentiviral human AGBL3 shRNA (UAS, RFP) plasmid
GTR15340312 1 Vial

Lentiviral human AGBL3 shRNA (UAS) - Lentiviral human AGBL3 shRNA (UAS, RFP) plasmid

Ask
View Details
Senp3 (NM_030702) Mouse Tagged ORF Clone Lentiviral Particle
MR224185L3V 200 µL

Senp3 (NM_030702) Mouse Tagged ORF Clone Lentiviral Particle

Ask
View Details
20nm Unconjugated Colloidal Gold
G-20-25 25 mL

20nm Unconjugated Colloidal Gold

Ask
View Details
Mouse Upp2 activation kit by CRISPRa
GA210573 1 Kit

Mouse Upp2 activation kit by CRISPRa

Ask
View Details
Recombinant Deinococcus geothermalis Glucose-1-phosphate adenylyltransferase (glgC)
MBS1340324-01 0.02 mg (E-Coli)

Recombinant Deinococcus geothermalis Glucose-1-phosphate adenylyltransferase (glgC)

Ask
View Details
Recombinant Deinococcus geothermalis Glucose-1-phosphate adenylyltransferase (glgC)
MBS1340324-02 0.02 mg (Yeast)

Recombinant Deinococcus geothermalis Glucose-1-phosphate adenylyltransferase (glgC)

Ask
View Details